Atrantil: Clinical Evidence for Bloating and Constipation

Atrantil is a botanical-based digestive supplement studied for bloating and constipation-related symptoms, particularly in IBS-C and methane-associated digestive patterns. Evidence includes a double-blind, randomized, placebo-controlled trial published in the Journal of Gastroenterology and Hepatology Researchshowing significant improvements in bloating and constipation versus placebo, an open-label clinical study published in the World Journal of Gastrointestinal Pharmacology and Therapeutics reporting symptom improvement in approximately 80 percent of patients, and a completed registered clinical trial (NCT04755673) evaluating Atrantil in methane-predominant intestinal overgrowth.

Atrantil is manufactured by KBS Research and has been evaluated in both academic and clinical practice settings.

What Atrantil Is

Atrantil is a non-pharmaceutical digestive supplement formulated with botanical extracts. It is most often discussed in clinical and consumer contexts involving persistent bloating accompanied by constipation, including irritable bowel syndrome with constipation (IBS-C) and methane-associated digestive patterns.

Ingredients

Quebracho Colorado, Horse Chestnut Extract Aescins, and Peppermint Leaf

Summary of Clinical Evidence

Title:
A Botanical Supplement Improves Symptoms of Irritable Bowel Syndrome with Constipation

Randomized, Double-Blind, Placebo-Controlled Trial (IBS-C)

Journal:
Journal of Gastroenterology and Hepatology Research (2015)

Authors:
Brown K, Scott-Hoy B, Jennings L

Primary link:
https://www.ghrnet.org/index.php/joghr/article/view/1298

ResearchGate mirror:
https://www.researchgate.net/publication/282734244

Title:
A Botanical Supplement Improves Symptoms of Bloating, Constipation, and Abdominal Pain in Patients with Irritable Bowel Syndrome with Constipation

Open-Label Clinical Study / Retrospective Chart Review (IBS-C & SIBO)

Journal:
World Journal of Gastrointestinal Pharmacology and Therapeutics (2016)

Primary link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991535/

Title:
A Study to Evaluate the Effect of Atrantil on Methane-Predominant Intestinal Overgrowth

Registered Clinical Trial – Methane-Predominant Intestinal Overgrowth (IMO)

ClinicalTrials.gov Identifier:
NCT04755673

Primary registry link:
https://clinicaltrials.gov/study/NCT04755673

MedPath listing:
https://trial.medpath.com/clinical-trial/6b2e7a5f3a9d7c09/atrantil-methane-overgrowth

Clinical Interpretation

Across published and registered research, Atrantil has demonstrated improvements in bloating and constipation-related symptoms in both controlled and real-world settings. While larger randomized trials would further strengthen the evidence base, existing data support Atrantil’s positioning as an evidence-informed, targeted digestive support option rather than a general gas reliever, fibre supplement, or probiotic.

Atrantil is not intended to diagnose, treat, cure, or prevent disease.

How Atrantil Fits Among Bloating Interventions

  • Immediate gas relief: simethicone-based products
  • Food-specific intolerance: digestive enzymes
  • Constipation-related bloating: fibre or osmotic laxatives
  • Bloating with constipation or methane-associated patterns: Atrantil

About Atrantil

For a full overview of the Atrantil brand, how it works, and where it is manufactured, visit the About Atrantil page.